Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. Zeder (Graz, Austria), A. Avian (Graz, Austria), G. Bachmaier (Graz, Austria), P. Douschan (Graz, Austria), V. Foris (Graz, Austria), T. Sassmann (Graz, Austria), H. Olschewski (Graz, Austria), G. Kovacs (Graz, Austria). Exercise Pulmonary Vascular Resistances are Predictors of Survival in Systemic Sclerosis. 1515

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary Vascular Resistances are Predictors of 3-year-survival in Systemic Sclerosis Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 Aerobic Training Improves Pulmonary and Systemic Inflammatory and Fibrotic Response in Asthmatics Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 Physical Training Improves Lung Function and Mechanics and Pulmonary and Systemic Immune Response in Eutrophic Women Source: Virtual Congress 2020 – Novel insights into exercise training Year: 2020 Pulmonary Hypertension in Pulmonary tuberculosis- A Prognostic Indicator Source: International Congress 2017 – Imaging and lung disease PH Year: 2017 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Multi-Omics Analysis of the PDGF Response in Pulmonary Vascular Smooth Muscle Cells from Patients with Pulmonary Arterial Hypertension: Implication of the NMDAR Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Late Breaking Abstract - Clinical Efficacy and Safety of Macitentan Transitioned from Bosentan in Patients with Pulmonary Arterial Hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Clinical Features of Pulmonary Hypertension Source: School Course 2012 - Pulmonary hypertension and pulmonary vascular disease Year: 2012 Patterns of Oxygen Pulse Response to Incremental Exercise in Patients with Chronic Obstructive Pulmonary Disease – An Observational Study Source: International Congress 2017 – Exercise testing in cardiorespiratory diseases Year: 2017 Aerobic and Weightlifting Training Improves Lung Function and Mechanics and Pulmonary and Systemic Immune Response in Overweight Women Source: Virtual Congress 2020 – Novel insights into exercise training Year: 2020 Impact of Pulmonary Hypertension on the Response to Pulmonary Rehabilitation in Obstructive Lung Disease Source: International Congress 2019 – The future of pulmonary rehabilitation discussed today Year: 2019 Effects of Ground-Based Walking Training in Pulmonary Hypertension Source: Virtual Congress 2020 – Muscle, exercise capacity and symptoms of chronic lung disease: a physio update Year: 2020 Clinical efficacy of Macitentan in patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Red Blood Cell Distribution Width as a potential predictor of Pulmonary Hypertension Secondary to Chronic Obstructive Pulmonary Disease Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Late Breaking Abstract - Balloon Pulmonary Angioplasty for the Treatment of Non Operable Chronic Thromboembolic Pulmonary Hypertension – Initial experience of a Belgian Center Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021